Table 1 Baseline characteristics of patients using triptans (2005–2008)
From: Treatment adherence among new triptan users: a 2-year cohort study in Taiwan
Number (percentage) | |
|---|---|
No. of patient | 13951 |
Female | 10736 (77.0) |
Age, mean (SD), years | 41.3 (13.7) |
Monthly income NT$ | |
Dependent | 2782 (19.9) |
NT 0–19,200 | 3837 (27.5) |
NT 19,200-42,000 | 5383 (38.6) |
>NT42,000 | 1949 (14.0) |
Urbanization | |
1 (Most urbanized) | 6639 (47.6) |
2 | 6528 (46.8) |
3 | 6741 (4.8) |
4 (Least urbanized) | 110 (0.8) |
Level of hospital | |
Level I (Medical center) | 6548 (46.9) |
Level II | 4425 (31.7) |
Level III | 2066 (14.8) |
Level IV (Local medical clinics) | 912 (6.5) |
Charlson comorbidity index score | |
Score 0 | 6521 (46.7) |
Score 1 | 3787 (27.2) |
Score 2 | 1849 (13.3) |
Score ≥3 | 1794 (12.9) |
Cardiovascular disease risk equivalent | |
Cerebrovascular disease | 1187 (8.5) |
Diabetes mellitus | 1287 (9.2) |
Peripheral vascular disease | 201 (1.4) |
Triptan prescription by a neurologist | 9396 (67.4) |
All ambulatory visits for any kind of disease within one year before, median (IQR) | 20 (11–35) |
All ambulatory visits for headache within one year before, median (IQR) | 1 (0–5) |
Neurologic ambulatory visits within one year before, median (IQR) | 0 (0–2) |
Neurologic ambulatory visits for headache within one year before, median (IQR) | 0 (0–1) |
Triptan only | 7784 (55.8) |
Triptan plus other acute medications | 6167 (44.2) |
Sumatriptan, oral | 13841 (99.2) |
Sumatriptan, nasal | 105 (0.75) |
Sumatriptan, oral + nasal | 1 (0.01) |
Rizatriptan | 4 (0.03) |
Prophylactic agents | |
Amitriptyline | 594 (4.3) |
Propranolol | 5995 (43.0) |
Valproic acid | 884 (6.3) |
Topiramate | 3237 (23.2) |
Flunarizine | 4294 (30.8) |
At least one prophylactic agent | 9397(67.4) |